Academic Journal
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study
| Title: | Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study |
|---|---|
| Authors: | Bettiol A., Urban M. L., Padoan R., Groh M., Lopalco G., Egan A., Cottin V., Fraticelli P., Crimi C., Del Giacco S., Losappio L., Moi L., Cinetto F., Caminati M., Novikov P., Berti A., Cameli P., Cathebras P., Coppola A., Durel C. -A., Folci M., Gullo A. L., Lombardi C., Monti S., Parronchi P., Rivera C. M., Solans R., Vacca A., Espigol-Frigole G., Guarnieri G., Bianchi F. C., Marchi M. R., Tcherakian C., Kahn J. -E., Iannone F., Venerito V., Desaintjean C., Moroncini G., Nolasco S., Costanzo G. A. M. L., Schroeder J. W., Ribi C., Tesi M., Gelain E., Mattioli I., Bello F., Jayne D., Prisco D., Vaglio A., Emmi G., European EGPA Study Group |
| Contributors: | Bettiol, Alessandra, Urban, Maria Letizia, Padoan, Roberto, Groh, Matthieu, Lopalco, Giuseppe, Egan, Allyson, Cottin, Vincent, Fraticelli, Paolo, Crimi, Claudia, Del Giacco, Stefano, Losappio, Laura, Moi, Laura, Cinetto, Francesco, Caminati, Marco, Novikov, Pavel, Berti, Alvise, Cameli, Paolo, Cathébras, Pascal, Coppola, Angelo, Durel, Cécile-Audrey, Folci, Marco, Gullo, Alberto Lo, Lombardi, Carlo, Monti, Sara, Parronchi, Paola, Rivera, Carlos Martinez, Solans, Roser, Vacca, Angelo, Espígol-Frigolé, Georgina, Guarnieri, Gabriella, Bianchi, Fulvia Chieco, Marchi, Maria Rita, Tcherakian, Cola, Kahn, Jean-Emmanuel, Iannone, Florenzo, Venerito, Vincenzo, Desaintjean, Charlene, Moroncini, Gianluca, Nolasco, Santi, Costanzo, Giulia Anna Maria Luigia, Schroeder, Jan Walter, Ribi, Camillo, Tesi, Michelangelo, Gelain, Elena, Mattioli, Irene, Bello, Federica, Jayne, David, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo |
| Source: | The Lancet Rheumatology. 5:e707-e715 |
| Publisher Information: | Elsevier BV, 2023. |
| Publication Year: | 2023 |
| Subject Terms: | Granulomatosis with Polyangiitis drug therapy, Male, Adult, benralizumab, EGPA, Interleukin-5, epa, Interleukin Inhibitors, Churg-Strauss Syndrome, Antibodies, Monoclonal, Humanized, Antibodies, Cohort Studies, Monoclonal, Humans, Humanized, Retrospective Studies, Granulomatosis with Polyangiitis, Middle Aged, Churg-Strauss Syndrome diagnosis, Benralizumab, eosinophils, EGPA, Adult, Antibodies, Monoclonal, Humanized, Churg-Strauss Syndrome diagnosis, Cohort Studies, Female, Granulomatosis with Polyangiitis drug therapy, Humans, Interleukin Inhibitors, Leukocyte Disorders, Male, Middle Aged, Pathologic Complete Response, Prednisone, Retrospective Studies, Pathologic Complete Response, Prednisone, Female, Benralizumab, biologics, Polyangiitis, Eosinophils, Leukocyte Disorders |
| Description: | Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA.This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022. We assessed the rates of complete response, defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] of 0) and a prednisone dose of up to 4 mg/day, in contrast to partial response, defined as a BVAS of 0 and a prednisone dose greater than 4 mg/day. Active disease manifestations, pulmonary function, variation in glucocorticoid dose, and safety outcomes were also assessed over a 12-month follow-up.121 patients with relapsing-refractory EGPA treated with benralizumab at the dose approved for eosinophilic asthma were included (64 [53%] women and 57 [47%] men; median age at the time of beginning benralizumab treatment 54·1 years [IQR 44·2-62·2]). Complete response was reported in 15 (12·4%, 95% CI 7·1-19·6) of 121 patients at month 3, 25 (28·7%, 19·5-39·4) of 87 patients at month 6, and 32 (46·4%, 34·3-58·8) of 69 patients at month 12; partial response was observed in an additional 43 (35·5%, 27·0-44·8) patients at month 3, 23 (26·4%, 17·6-37·0) at month 6, and 13 (18·8%, 10·4-30·1) at month 12. BVAS dropped from 3·0 (IQR 2·0-8·0) at baseline to 0·0 (0·0-2·0) at months 3 and 6, and to 0·0 (0·0-1·0) at month 12. The proportion of patients with systemic manifestations, active peripheral neurological disease, ear, nose, and throat involvement, and pulmonary involvement decreased, with an improvement in lung function tests. Six patients relapsed after having a complete response. The oral prednisone (or equivalent) dose decreased from 10·0 mg/day (5·0-12·5) at baseline to 5·0 mg/day (3·6-8·5) at month 3 (p |
| Document Type: | Article |
| File Description: | application/pdf; ELETTRONICO |
| Language: | English |
| ISSN: | 2665-9913 |
| DOI: | 10.1016/s2665-9913(23)00243-6 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/38251561 https://www.sciencedirect.com/science/article/abs/pii/S2665991323002436 https://doi.org/10.1016/S2665-9913(23)00243-6 https://hdl.handle.net/11365/1255765 https://www.sciencedirect.com/science/article/abs/pii/S2665991323002436?via=ihub https://doi.org/10.1016/s2665-9913(23)00243-6 https://hdl.handle.net/11572/456174 https://www.sciencedirect.com/science/article/abs/pii/S2665991323002436?via=ihub https://hdl.handle.net/11368/3098832 https://doi.org/10.1016/S2665-9913(23)00243-6 https://hdl.handle.net/11584/387693 https://doi.org/10.1016/S2665-9913(23)00243-6 |
| Rights: | Elsevier TDM |
| Accession Number: | edsair.doi.dedup.....5dba65e494a21bd7c3648e626e0774e7 |
| Database: | OpenAIRE |
| ISSN: | 26659913 |
|---|---|
| DOI: | 10.1016/s2665-9913(23)00243-6 |